// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Monitoring of steroid-induced side-effects in a severe asthma service

Holly Stokes - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Evaluation of delivered dose and treatment time of several mesh nebulizers under in vitro simulated use

Lois Slator - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Salbutamol

Pressurized Metered Dose Inhaler (pMDI) Delivery to Infants via Valved Holding Chamber (VHC) with Facemask: Not All VHCs Perform the Same

Amanda Bracey - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Salbutamol

Effect of breath-actuated mechanism on the emitted particle characteristics and lung deposition of a fixed combination drug

Arpad Farkas - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Effect of CHF5993 pMDI (extrafine Beclometasone Dipropionate:BDP,Formoterol Fumarate:FF,Glycopyrronium Bromide:GB) on Clinically Important Deteriorations (CID) in COPD: post-hoc analysis of TRINITY study

Dave Singh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

beclometasone dipropionate

Systemic bioavailability (BA) and pharmacodynamics (PD) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) or a novel breath-triggered inhaler (BTI)

David Bell - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Fluticasone propionate

Mepolizumab in patients ≥3 exacerbations and eosinophil count ≥300 cells/µL

Steven Yancey - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Mepolizumab

Omalizumab in severe allergic asthma: a 4-year real world experience, Fife, Scotland

Devesh Dhasmana - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Omalizumab

Effects of Omalizumab treatment on nasal symptoms (SNOT score) in patients treated for severe asthma

Douglas Robinson - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Omalizumab

Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma

Rahul Shrimanker - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Prednisolone

Is it possible to predict asthma outcomes? A disease model for economic analysis

Kevin Marsh - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

N/A

Seasonality of asthma exacerbations: efficacy of fluticasone furoate/vilanterol 100/25µg (FF/VI) vs fluticasone furoate 100µg (FF) alone

Courtney Crim - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Fluticasone furoate

Novel nebulisation of budesonide as add-on treatment in uncontrolled asthmatics

Gary Burgess - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Asthma

Budesonide

Clinically important deterioration in advanced COPD patients using single inhaler triple therapy: results from the FULFIL study

Ian Naya - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

fluticasone furoate/umeclidinium/vilanterol

Early occurrence of any COPD exacerbation predicts further higher risk of moderate/severe exacerbations regardless of recording tool: the FLAME study

Jadwiga Wedzicha - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

salmeterol + fluticasone

NMR-based metabolomics of exhaled breath condensate for assessing the effects of inhaled corticosteroids in COPD patients

Paolo Montuschi - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Advair HFA

Target engagement confirmed in man with a dipeptidyl peptidase 1 inhibitor

Kristina Stenvall - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

AZD-7986

Population pharmacokinetic (PK) analysis of fluticasone furoate (FF)/umeclidimium (UMEC)/vilanterol (VI) via a single inhaler in patients with COPD (FULFIL)

Rashmi Mehta - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

Fluticasone furoate

Symptomatic burden of COPD for patients receiving dual or triple therapy

Stephanie Chen - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Chronic obstructive pulmonary disease

N/A

A randomized placebo controlled trial of AZD8871 a novel dual acting bronchodilator in asthmatics

Lali Jimenez - European Respiratory Society (ERS) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Asthma

N/A

Copyright © 2026. QuantiNova All rights reserved